Pharmacy benefit managers are the middlemen in the prescription drug market. The Federal Trade Commission reports the revenue of four PBMs exceeds $1 trillion and they control 86% of the market.
(Reuters) -Cigna Group plans to make changes to help lower out-of-pocket cost of prescription drugs, the company said on ...
In a recent antitrust arbitration ruling, Prime Therapeutics, a pharmacy benefit manager (PBM) owned by 19 Blue Cross and ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
As the year begins under a new Trump Administration, healthcare providers and private equity firms should consider the antitrust ...
3don MSNOpinion
As the 119th Congress convenes, policymakers have a historic opportunity to lower prescription drug prices for Americans. As ...
The report shows that PBMs made over $7.3 billion in extra profits from dispensing specialty generic drugs during the study ...
Independent drugstores are closing at an alarming rate, squeezed by the huge companies that reimburse pharmacies for costly ...
Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...
A bill that aims to increase pharmacy benefit managers’ transparency by requiring them to report data to the agency that ...
Mintz’s Health Law and Antitrust teams actively monitor federal and state regulatory and legislative developments in the PBM ...
In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback